Avellino Lab USA has introduced a new multi-panel RT-PCR-based virus assay, AvellinoCoV2 – Respiratory Test.

From a single sample, the new assay is designed to detect four viral infections, namely Covid-19, respiratory syncytial virus (RSV), influenza A and influenza B.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company stated that the assay’s new expanded panel comes with 100% sensitivity for the detection of RSV and influenza A and B, as well as more than 99% accuracy for RSV and 100% accuracy for influenza A and B.

The Covid-19 panel in the AvellinoCoV2 – Respiratory Test analyses the N gene and can identify the presence of the Omicron variant, including BA.2, along with all other known variants of the virus.

Additionally, the new assay has the capability to detect flurona, which is a term used for a Covid-19 and influenza co-infection, or any other combination of the detectable viruses.

Last month, the first cases of flurona were detected in the US states of Texas and California.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Avellino chief scientific officer Nazneen Aziz said: “We are in an unprecedented cold and flu season, with Covid-19, RSV and the emerging flurona infections as continued health hazards.

“The expanded AvellinoCoV2 – Respiratory Test supports the Centers for Disease Control and Prevention’s (CDC) notice last June to expand RSV testing, as well as the physician need to test for both Covid-19 and influenza, which is now even more important with the emergence of flurona.

“With accurate and early diagnosis medical care professionals can make appropriate patient management decisions and better utilise medical resources.”

Besides a rapid antigen Covid-19 test that can identify the SARS CoV-2 presence, the firm distributes an antibody test kit that detects the presence of Covid-19 S protein antibodies, which can be acquired through vaccinations or earlier SARS-CoV-2 infections.

Through whole-genome sequencing of positive samples in its database, Avellino also undertakes surveillance of the several variants circulating in the community.

The company stated that the test samples, which are collected using a mid-turbinate nasal swab, will be sent to a Clinical Laboratory Improvement Amendments (CLIA) certified Avellino laboratory for analysis.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now